Phaseline

Companies › Inventprise

Inventprise: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 2, 2 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IVT PCV-25 (Formulation B)
25-valent pneumococcal conjugate vaccine
–Phase 2Pneumococcal Disease, InvasiveDec 2026
IVT GBS-06
Hexavalent Group B Streptococcus polysaccharide conjugate vaccine (serotypes Ia, Ib, II, I
–Phase 1Group B Streptococcal Infections–
IVT Shigella-04
Live attenuated Shigella vaccine targeting 4 serotypes
–Phase 1Shigella–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06611371IVT GBS-06Phase 1Group B Streptococcal InfectionsInfectious diseaseAug 2025
NCT07205926IVT Shigella-04Phase 1ShigellaInfectious diseaseJan 2026
NCT06790290IVT PCV-25 (Formulation B)Phase 2Pneumococcal Disease, InvasiveInfectious diseaseDec 2026
NCT06790290IVT PCV-25 (Formulation B)Phase 2Pneumococcal Disease, InvasiveInfectious diseaseDec 2026
NCT06790290IVT PCV-25 (Formulation B)Phase 2Pneumococcal Disease, InvasiveInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

LimmaTech Biologics SK Bioscience Green Cross Immorna Biotherapeutics Osivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.